Home » Topics » Regulatory » EMA

EMA
RSS

Novartis Europharm withdraws Rasival MAA for essential hypertension

Sep. 21, 2010

GSK investigates reports of narcolepsy following Pandemrix vaccination

Sep. 6, 2010

MSD's Sycrest approved in Europe for biopolar disorder

Sep. 3, 2010

FDA approves Bionovo's CMC plan for Menerba

Aug. 31, 2010

EMA investigates potential relationship between Pandemrix and narcolepsy

Aug. 30, 2010

European Commission updates license for Cervarix HPV vaccine

Aug. 30, 2010

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Aug. 27, 2010

Bristol-Myers Squibb offers pipeline update for Q2 2010

Aug. 24, 2010

Amsterdam Molecular Therapeutics provides update on Glybera MAA

Aug. 23, 2010

EMA accepts Optimer Pharma's fidaxomicin MAA for review

Aug. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 25, 2025.
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 24, 2025
Clots and metastasis in cancer patients start in the lung
BioWorld MedTech
The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...